• Toxicological Research
• /
• v.19 no.4
• /
• pp.321-324
• /
• 2003

Antigenic potential of a novel cephalosporin, IDC7181 was examined a active systemic anaphylaxis (ASA) and passive cutaneous anaphylaxis (PCA) test, in guinea pig and mouse-rat models, respectively. In ASA test, IDC7181 induced the signs of restlessness in a few animals immunized with a high dose (100 mg/kg) of IDC7181 alone or in combination with Freund's complete adjuvant (FCA). In PCA test, only one of ten sera from the animals immunized with a high dose (100 mg/kg) of IDC7181 in the absence or presence of FCA showed positive reaction. The positive reaction, induced by IDC7181, which may be due to $\beta$-lactam ring, in ASA and PCA tests were negligible in comparison with those of traditional cephalosporins. Taken together, it is suggested that IDC7181 do not cause immunological problems in clinical dosage.

• Toxicological Research
• /
• v.18 no.2
• /
• pp.195-203
• /
• 2002

This study was performed to evaluate single and repeated-dose toxicities oj a new cophalosporin antibiotic agent IDC-7l81 in Sprague-Dawley rats. IDC-7181 was injected intravenously to rats at dose levels of 0, 3.2, 16, 80, 400 and 2,000 mg/kg/day for single-dose toxicity study and at dose levels of 0, 10, 50 and 250 mg/kg/day for 4-week repeated-dose toxicity study. In both studies, there were no dose-related changes in mortality clinical signs, body weight changes, food and water consumption, opthalmoscopy, organ weights, urine analysis, biochemical examination, and hematological findings of all animals treated with IDC-7l8l. Gross and histopathological findings revealed no evidence of specific toxicity related to IDC-7181. These results suggest that the intravenous maximum tolerated dose value of IDC-7181 may be over 250 mg/kg and $LD_{50}$ value may be over 2,000 mg/kg in rats.

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.05a
• /
• pp.120-120
• /
• 2002

This study was designed to evaluate a repeated intravenous toxicity of a novel cephalosporin antibiotic, IDC7181, in Beagle dogs. Four groups, each consisting of 3 male and 3 female dogs (one year old, body weight 8 - 10 kg), were intravenously administered with IDC7181 at dose levels of 0 (vehicle control), 10, 50 or 250 mg/kg/day, respectively, for 28 days.(omitted)

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2001.10a
• /
• pp.169-169
• /
• 2001

This study was designed to evaluate an acute and subacute intravenous dose toxicity of a new cephalosporin antibiotic agent, IDC-7181 in 7-week-old Sprague-Dawley rats. IDC-7181 was intravenously injected to rats at dose levels of 0, 3.2, 16, 80, 400 and 2, 000 mg/kg/day for single dose toxicity study and at dose levels of 0, 10, 50 and 250 mg/kg/day for 4 week-repeated dose toxicity study. All rats survived throughout the study periods.(omitted)

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2001.10a
• /
• pp.180-180
• /
• 2001

The mutagenic potency of a new antibiotics, IDC- 7181, was evaluated using the mutagenicity tests including Ames, chromosome aberration and micronucleus tests. In bacterial reversion assay, IDC-7181 did not show any mutagenic response in the absence or presence of S9 mixture with Salmonella typhimurium TA98, TAlOO, TA1535 and TA1537 and E. coli WP2uvrA-(100, 50, 25, 12.5 and 6.25 $\mu\textrm{g}$/plate).(omitted)

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2002.05a
• /
• pp.120-120
• /
• 2002

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2001.10b
• /
• pp.180-180
• /
• 2001

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2001.10b
• /
• pp.169-169
• /
• 2001